Filing Details
- Accession Number:
- 0000899243-22-026768
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-07-26 20:15:02
- Reporting Period:
- 2022-07-25
- Accepted Time:
- 2022-07-26 20:15:02
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1787400 | Nkarta Inc. | NKTX | Pharmaceutical Preparations (2834) | 474515206 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1853197 | Ralph Brandenberger | C/O Nkarta, Inc., 6000 Shoreline Court, Suite 102 South San Francisco CA 94080 | Chief Technical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-07-25 | 3,000 | $0.41 | 10,800 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-07-25 | 3,000 | $13.41 | 7,800 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2022-07-25 | 3,000 | $0.00 | 3,000 | $0.41 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
4,367 | 2028-07-18 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person at least 30 days prior to the trade date.
- This transaction was executed in multiple trades at prices ranging from $13.29 to $13.59. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- This stock option is fully vested.